These novel RNAi agents directed against TGF-β1mRNA ameliorate outcomes and showed no off-target effects in wild type and human TGF-β1 TG mice with ALI and in wild type mice with pulmonary fibrosis, thereby supporting the pathological relevance of TGF-β1 in lung diseases. This evidence concerns the gene TGFB1 and lung disorder.